EVOHEALTH has now released its latest Cell and gene therapies (CGTs): Rising to the challenge Scorecard 2023 and is calling on the Government to accelerate the rate of progress for these innovative forms of treatment.
The Scorecard measures the nation's progress towards timely and equitable access to cell and gene therapies and highlights that Australia is behind other countries when it comes to our preparedness to embrace CGTs.
Managing Director Renae Beardmore said, "we must move faster if we are to capitalise on the benefit of CGTs...as with over 2,000 CGTs in the global pipeline, policy and system change that enables timely and equitable access to emerging innovative therapies, is important for people living with rare and genetic diseases".
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jun 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jun 23
